Top

Journal of Cardiothoracic Surgery

Published in:

Open Access 01-12-2021 | Pneumothorax | Research article

Complications of thoracoscopic talc insufflation for the treatment of malignant pleural effusions: a meta-analysis

Authors: Wen Zhang, Yun-long Zhao, Shao-jun Li, Ying-nan Zhao, Nan-nan Guo, Bo Liu

Published in: Journal of Cardiothoracic Surgery | Issue 1/2021

Abstract

Background

Talc pleurodesis is an effective treatment for malignant pleural effusions (MPEs). This study was designed to estimate complication rates of thoracoscopic talc insufflation.

Methods

Literature search was conducted in electronic databases and studies were selected if they reported complication rates of thoracoscopic talc insufflation in cancer patients with MPEs. Meta-analyses of proportions were performed to obtain incidence rates of complications.

Results

Twenty-six studies (4482 patients; age 62.9 years [95% confidence interval (CI): 61.5, 64.4]; 50% [95% CI: 43, 58] females) were included. Intraoperative, perioperative, 30-day, and 90-day mortality rates were 0% [95% CI: 0, 1], 2% [95% CI: 0, 4], 7% [95% CI: 3, 13] and 21% [95% CI: 5, 43] respectively. Incidence rates [95% CI] of various complications were: pain (20% [1, 2]), fever (14% [3, 4]), dyspnea (13% [5, 6]), pneumothorax (6% [7, 8]) pneumonia (4% [0, 12]), emphysema (3% [3, 7]), prolonged air leakage (3% [0, 7]), prolonged drainage (3% [9, 10]), thromboembolism (3% [9, 11]), lung injury (2% [7, 12]), respiratory insufficiency (2% [0, 5]), re-expansion pulmonary edema (1% [0, 3]), empyema (1% [0, 2]), respiratory failure (0% [0, 1]), and acute respiratory distress syndrome (ARDS; 0% [0, 1].

Conclusions

Whereas pain and fever were the most frequent complications of thoracoscopic talc insufflation, the incidence of ARDS was low. Pneumothorax, pneumonia, emphysema, prolonged air leakage, pulmonary embolism, arrythmia, re-expansion pulmonary edema, and empyema are important complications of thoracoscopic talc insufflation.

Available only for authorised users

Donnenberg AD, Luketich JD, Dhupar R, Donnenberg VS. Treatment of malignant pleural effusions: the case for localized immunotherapy. J Immunother Cancer. 2019;7(1):110 https://doi.org/10.1186/s40425-019-0590-4.CrossRefPubMedPubMedCentral

Antony VB, Jantz MA. Pleural effusions. Malignant Pleural Effusions. Encyclopedia Respir Med. 2006; https://doi.org/10.1016/B0-12-370879-6/00304-5.

American Thoracic Society. Management of malignant pleural effusions. Am J Respir Crit Care Med. 2000;162(5):1987–2001.CrossRef

Dresler CM. Systemic distribution of talc. Chest. 1999;166(1):266.CrossRef

Fortin M, Tremblay A. Pleural controversies: indwelling pleural catheter vs. pleurodesis for malignant pleural effusions. J Thorac Dis. 2015;7(6):1052–7 https://doi.org/10.3978/j.issn.2072-1439.2015.01.51.PubMedPubMedCentral

Keshishyan S, Harris K. Asymptomatic malignant pleural effusion: to observe or to manage. J Thorac Dis. 2017;9(Suppl 10):S1146–7 https://doi.org/10.21037/jtd.2017.06.52.CrossRefPubMedPubMedCentral

Light RW. Counterpoint: should thoracoscopic talc pleurodesis be the first choice management for malignant pleural effusion? No. Chest. 2012;142(1):17–9 https://doi.org/10.1378/chest.12-1087.CrossRefPubMed

Bibby AC, Dorn P, Psallidas I, Porcel JM, Janssen J, Froudarakis M, et al. ERS/EACTS statement on the management of malignant pleural effusions. Eur Respir J. 2018;52(1):1800349 https://doi.org/10.1183/13993003.00349-2018.CrossRefPubMed

Pilling JE, Dusmet ME, Ladas G, Goldstraw P. Prognostic factors for survival after surgical palliation of malignant pleural effusion. J Thorac Oncol. 2010;5(10):1544–50 https://doi.org/10.1097/JTO.0b013e3181e95cb8.CrossRefPubMed

10.

Yoon DW, Cho JH, Choi YS, Kim J, Kim HK, Zo J, et al. Predictors of survival in patients who underwent video-assisted thoracic surgery talc pleurodesis for malignant pleural effusion. Thorac Cancer. 2016;7(4):393–8 https://doi.org/10.1111/1759-7714.12354.CrossRefPubMedPubMedCentral

11.

Abrao FC, de Abreu IRLB, de Oliveira MC, Viana GG, Filho JF, Younes RN, et al. Prognostic factors of recurrence of malignant pleural effusion: what is the role of neoplasia progression? J Thorac Dis. 2020;12(3):813–22 https://doi.org/10.21037/jtd.2020.01.13.CrossRefPubMedPubMedCentral

12.

Xia H, Wang XJ, Zhou Q, Shi HZ, Tong ZH. Efficacy and safety of talc pleurodesis for malignant pleural effusion: a meta-analysis. PLoS One. 2014;9(1):e87060 https://doi.org/10.1371/journal.pone.0087060.CrossRefPubMedPubMedCentral

13.

Dipper A, Jones HE, Bhatnagar R, Preston NJ, Maskell N, Clive AO. Interventions for the management of malignant pleural effusions: a network meta-analysis. Cochrane Database Syst Rev. 2020;4(4):CD010529 https://doi.org/10.1002/14651858.CD010529.pub3.PubMed

14.

Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health. 2014;72(1):39 https://doi.org/10.1186/2049-3258-72-39.CrossRefPubMedPubMedCentral

15.

Aelony Y, Yao JF. Prolonged survival after talc poudrage for malignant pleural mesothelioma: case series. Respirology. 2005;10(5):649–55. https://doi.org/10.1111/j.1440-1843.2005.00763.x.CrossRefPubMed

16.

Arapis K, Caliandro R, Stern JB, Girard P, Debrosse D, Gossot D. Thoracoscopic palliative treatment of malignant pleural effusions: results in 273 patients. Surg Endosc. 2006;20(6):919–23. https://doi.org/10.1007/s00464-005-0534-6.CrossRefPubMed

17.

Barbetakis N, Asteriou C, Papadopoulou F, Samanidis G, Paliouras D, Kleontas A, et al. Early and late morbidity and mortality and life expectancy following thoracoscopic talc insufflation for control of malignant pleural effusions: a review of 400 cases. J Cardiothorac Surg. 2010;5:27. https://doi.org/10.1186/1749-8090-5-27.CrossRefPubMedPubMedCentral

18.

Bhatnagar R, Piotrowska HEG, Laskawiec-Szkonter M, Kahan BC, Luengo-Fernandez R, Pepperell JCT, et al. Effect of thoracoscopic talc poudrage vs talc slurry via chest tube on pleurodesis failure rate among patients with malignant pleural effusions: a randomized clinical trial. JAMA. 2019;323(1):60–9. https://doi.org/10.1001/jama.2019.19997.CrossRefPubMedCentral

19.

Cardillo G, Facciolo F, Carbone L, Regal M, Corzani F, Ricci A, et al. Long-term follow-up of video-assisted talc pleurodesis in malignant recurrent pleural effusions. Eur J Cardiothorac Surg. 2002;21(2):302–5; discussion 305-6. https://doi.org/10.1016/s1010-7940(01)01130-7.CrossRefPubMed

20.

Daniel TM, Tribble CG, Rodgers BM. Thoracoscopy and talc poudrage for pneumothoraces and effusions. Ann Thorac Surg. 1990;50(2):186–9. https://doi.org/10.1016/0003-4975(90)90730-t.CrossRefPubMed

21.

de Campos JR, Vargas FS, de Campos Werebe E, Cardoso P, Teixeira LR, et al. Thoracoscopy talc poudrage: a 15-year experience. Chest. 2001;119(3):801–6. https://doi.org/10.1378/chest.119.3.801.CrossRefPubMed

22.

Debeljak A, Kecelj P, Triller N, Letonja S, Kern I, Debevec L, et al. Talc pleurodesis: comparison of talc slurry instillation with thoracoscopic talc insufflation for malignant pleural effusions. J BUON. 2006;11(4):463–7.PubMed

23.

Diacon AH, Wyser C, Bolliger CT, Tamm M, Pless M, Perruchoud AP, et al. Prospective randomized comparison of thoracoscopic talc poudrage under local anesthesia versus bleomycin instillation for pleurodesis in malignant pleural effusions. Am J Respir Crit Care Med. 2000;162(4 Pt 1):1445–9. https://doi.org/10.1164/ajrccm.162.4.2002030.CrossRefPubMed

24.

Dresler CM, Olak J, Herndon JE 2nd, Richards WG, Scalzetti E, Fleishman SB, et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest. 2005;127(3):909–15. https://doi.org/10.1378/chest.127.3.909.CrossRefPubMed

25.

Froudarakis ME, Klimathianaki M, Pougounias M. Systemic inflammatory reaction after thoracoscopic talc poudrage. Chest. 2006;129(2):356–61. https://doi.org/10.1378/chest.129.2.356.CrossRefPubMed

26.

Fysh ET, Tan SK, Read CA, Lee F, McKenzie K, Olsen N, et al. Pleurodesis outcome in malignant pleural mesothelioma. Thorax. 2013;68(6):594–6. https://doi.org/10.1136/thoraxjnl-2012-203043.CrossRefPubMed

27.

Gonzalez AV, Bezwada V, Beamis JF Jr, Villanueva AG. Lung injury following thoracoscopic talc insufflation: experience of a single North American center. Chest. 2010;137(6):1375–81. https://doi.org/10.1378/chest.09-2020.CrossRefPubMed

28.

Guo H, Wan Y, Tian G, Liu Q, Kang Y, Li Y, et al. EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy. Oncol Rep. 2012;27(3):880–90. https://doi.org/10.3892/or.2011.1559.CrossRefPubMed

29.

Hunt BM, Farivar AS, Vallières E, Louie BE, Aye RW, Flores EE, et al. Thoracoscopic talc versus tunneled pleural catheters for palliation of malignant pleural effusions. Ann Thorac Surg. 2012;94(4):1053–7; discussion 1057-9. https://doi.org/10.1016/j.athoracsur.2012.01.103.CrossRefPubMed

30.

Inoue T, Ishida A, Nakamura M, Nishine H, Mineshita M, Miyazawa T. Talc pleurodesis for the management of malignant pleural effusions in Japan. Intern Med. 2013;52(11):1173–6. https://doi.org/10.2169/internalmedicine.52.9281.CrossRefPubMed

31.

Janssen JP, Collier G, Astoul P, Tassi GF, Noppen M, Rodriguez-Panadero F, et al. Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. Lancet. 2007;369(9572):1535–9. https://doi.org/10.1016/S0140-6736(07)60708-9.CrossRefPubMed

32.

Kolschmann S, Ballin A, Gillissen A. Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions. Chest. 2005;128(3):1431–5. https://doi.org/10.1378/chest.128.3.1431.CrossRefPubMed

33.

Laisaar T, Palmiste V, Vooder T, Umbleja T. Life expectancy of patients with malignant pleural effusion treated with video-assisted thoracoscopic talc pleurodesis. Interact Cardiovasc Thorac Surg. 2006;5(3):307–10. https://doi.org/10.1510/icvts.2005.118018.CrossRefPubMed

34.

Leuzzi G, Vita ML, Porziella V, Congedo MT, Cesario A. Single center experience on talc poudrage morbidity: focus on high talc dosage. J Cardiothorac Surg. 2011;6:87. https://doi.org/10.1186/1749-8090-6-87.CrossRefPubMedPubMedCentral

35.

Love D, White D, Kiroff G. Thoracoscopic talc pleurodesis for malignant pleural effusion. ANZ J Surg. 2003;73(1-2):19–22. https://doi.org/10.1046/j.1445-2197.2003.02616.x.CrossRefPubMed

36.

Mohsen TA, Zeid AA, Meshref M, Tawfeek N, Redmond K, Ananiadou OG, et al. Local iodine pleurodesis versus thoracoscopic talc insufflation in recurrent malignant pleural effusion: a prospective randomized control trial. Eur J Cardiothorac Surg. 2011;40(2):282–6. https://doi.org/10.1016/j.ejcts.2010.09.005.CrossRefPubMed

37.

Reddy C, Ernst A, Lamb C, Feller-Kopman D. Rapid pleurodesis for malignant pleural effusions: a pilot study. Chest. 2011;139(6):1419–23. https://doi.org/10.1378/chest.10-1868.CrossRefPubMed

38.

Stefani A, Natali P, Casali C, Morandi U. Talc poudrage versus talc slurry in the treatment of malignant pleural effusion. A prospective comparative study. Eur J Cardiothorac Surg. 2006;30(6):827–32. https://doi.org/10.1016/j.ejcts.2006.10.002.CrossRefPubMed

39.

Viallat JR, Rey F, Astoul P, Boutin C. Thoracoscopic talc poudrage pleurodesis for malignant effusions. A review of 360 cases. Chest. 1996;110(6):1387–93. https://doi.org/10.1378/chest.110.6.1387.CrossRefPubMed

40.

Yim AP, Chan AT, Lee TW, Wan IY, Ho JK. Thoracoscopic talc insufflation versus talc slurry for symptomatic malignant pleural effusion. Ann Thorac Surg. 1996;62(6):1655–8.CrossRefPubMed

41.

Habal P, Jankovicova K, Omran N, Kondelkova K, Krejsek J, Mandak J. The dynamics of selected local inflammatory markers to talc in the treatment of malignant pleural effusions. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013;157(4):311–5. https://doi.org/10.5507/bp.2012.095.CrossRefPubMed

42.

Thomas R, Francis R, Davies HE, Lee YC. Interventional therapies for malignant pleural effusions: the present and the future. Respirology. 2014;19(6):809–22. https://doi.org/10.1111/resp.12328.CrossRefPubMed

43.

Maskell NA, Lee YC, Gleeson FV, Hedley EL, Pengelly G, Davies RJ. Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size. Am J Respir Crit Care Med. 2004;170(4):377–82. https://doi.org/10.1164/rccm.200311-1579OC.CrossRefPubMed

44.

Arellano-Orden E, Romero-Falcon A, Juan JM, Ocaña Jurado M, Rodriguez-Panadero F, Montes-Worboys A. Small particle-size talc is associated with poor outcome and increased inflammation in thoracoscopic pleurodesis. Respiration. 2013;86(3):201–9. https://doi.org/10.1159/000342042.CrossRefPubMed

45.

Genofre EH, Vargas FS, Acencio MM, Antonangelo L, Teixeira LR, Marchi E. Talc pleurodesis: evidence of systemic inflammatory response to small size talc particles. Respir Med. 2009;103(1):91–7. https://doi.org/10.1016/j.rmed.2008.07.021.CrossRefPubMed

46.

Rehse DH, Aye RW, Florence MG. Respiratory failure following talc pleurodesis. Am J Surg. 1999;177(5):437–40. https://doi.org/10.1016/s0002-9610(99)00075-6.CrossRefPubMed

47.

Brant A, Eaton T. Serious complications with talc slurry pleurodesis. Respirology. 2001;6(3):181–5. https://doi.org/10.1046/j.1440-1843.2001.00327.x.CrossRefPubMed

48.

Rinaldo JE, Owens GR, Rogers RM. Adult respiratory distress syndrome following intrapleural instillation of talc. J Thorac Cardiovasc Surg. 1983;85(4):523–6.CrossRefPubMed

49.

Shinno Y, Kage H, Chino H, Inaba A, Arakawa S, Noguchi S, et al. Old age and underlying interstitial abnormalities are risk factors for development of ARDS after pleurodesis using limited amount of large particle size talc. Respirology. 2018;23(1):55–9. https://doi.org/10.1111/resp.13192.CrossRefPubMed

50.

Davies HE, Mishra EK, Kahan BC, Wrightson JM, Stanton AE, Guhan A, et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA. 2012;307(22):2383–9. https://doi.org/10.1001/jama.2012.5535.CrossRefPubMed

51.

Genofre EH, Marchi E, Vargas FS. Inflammation and clinical repercussions of pleurodesis induced by intrapleural talc administration. Clinics (Sao Paulo). 2007;62(5):627–34. https://doi.org/10.1590/s1807-59322007000500015.CrossRef

52.

Lee YC, Baumann MH, Maskell NA, Waterer GW, Eaton TE, Davies RJ, et al. Pleurodesis practice for malignant pleural effusions in five English-speaking countries: survey of pulmonologists. Chest. 2003;124(6):2229–38. https://doi.org/10.1378/chest.124.6.2229.CrossRefPubMed

53.

Marchi E, Vargas FS, Madaloso BA, Carvalho MV, Terra RM, Teixeira LR. Pleurodesis for malignant pleural effusions: a survey of physicians in South and Central America. J Bras Pneumol. 2010;36(6):759–67. https://doi.org/10.1590/s1806-37132010000600014.CrossRefPubMed

Title: Complications of thoracoscopic talc insufflation for the treatment of malignant pleural effusions: a meta-analysis
Authors: Wen Zhang
Yun-long Zhao
Shao-jun Li
Ying-nan Zhao
Nan-nan Guo
Bo Liu
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Pneumothorax
Pulmonary Edema
Pleural Effusion
Pneumothorax
Thoracoscopy
Pneumothorax
Acute Respiratory Distress-Syndrome
Pleurodesis
Published in: Journal of Cardiothoracic Surgery / Issue 1/2021
Electronic ISSN: 1749-8090
DOI: https://doi.org/10.1186/s13019-021-01475-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Complications of thoracoscopic talc insufflation for the treatment of malignant pleural effusions: a meta-analysis

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Video-assisted pulmonary metastectomy is equivalent to thoracotomy regarding resection status and survival

Feasibility of structured light Plethysmography (SLP) in patients with coronavirus disease 2019 (COVID-19)

Body mass index is an independent predictor of acute kidney injury after urgent aortic arch surgery for acute DeBakey Type I aortic dissection

Neonatal repair of total anomalous pulmonary venous connection accompanied by unilateral lung agenesis and Goldenhar syndrome: a case report

Short-term assessment of radial artery grafts with multidetector computed tomography

Case report of a 72-year-old man with diaphragmatic hernia and thoracic gastropericardial fistula after esophagectomy for 18 years